A Beijing court is likely to hold further hearings on legal challenges by suppliers of active pharmaceutical ingredients to a decision by the country’s top competition regulator to impose record antitrust penalties on the companies, MLex has learned. Last April, the State Administration for Market Regulation, or SAMR, announced a penalty decision on